Response Genetics to work with Roche on PCR analysis
This article was originally published in Clinica
Executive Summary
Roche Diagnostics is set to use Response Genetics’ PCR analysis technology to assess human epidermal growth factor type 2 (HER2) gene expression. Response granted Roche a non-exclusive license to the technology – financial terms of the collaboration were not disclosed. According to Los Angeles, California-based Response, the accurate measurement of HER2 gene expression can help professionals make treatment decisions for patients with breast cancer. Studies have shown that women with HER2-positive gene expression are three times more likely to have recurring cancer, even if the cancer is caught in the early stages. Roche and Response have combined previously in 2006, when the two firms worked alongside Eli Lilly to confirm biomarkers used to identify patients most likely to respond to certain cancer therapies.